5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyriMidin-3-yl]quinoline - Names and Identifiers
5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyriMidin-3-yl]quinoline - Physico-chemical Properties
Molecular Formula | C25H22N6
|
Molar Mass | 406.48 |
Density | 1.33±0.1 g/cm3(Predicted) |
Solubility | DMSO: soluble1mg/mL, clear (warmed) |
Appearance | powder |
Color | white to beige |
pKa | 8.79±0.10(Predicted) |
Storage Condition | 2-8°C |
In vitro study | In myofibroblast C2C12 cells, LDN-212854 showed higher selectivity to BMP6 for BMP6 and BMP4 induced osteogenic differentiation. In myofibroblast C2C12 cells, LDN-212854 showed higher selectivity to BMP6 for BMP6 and BMP4 induced osteogenic differentiation. href="#s_ref" class="sref">[1] |
In vivo study | LDN-212854(6 mg/kg, I. P.) was effective in disabling ALK2 signaling in vivo and in inhibiting heterotopic ossification in an inducible transgenic mutant ALK2 mouse model of Fibrodysplasia of ossification. LDN-212854(6 mg/kg, I. P.) effectively disabled ALK2 signaling in vivo, and effectively inhibits heterotopic ossification in an inducible transgenic mutant ALK2 mouse model of Fibrodysplasia of progressive ossification. |
5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyriMidin-3-yl]quinoline - Risk and Safety
Hazard Symbols | Xn - Harmful
|
Risk Codes | 22 - Harmful if swallowed
|
WGK Germany | 3 |
5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyriMidin-3-yl]quinoline - Preparation solution concentration reference
| 1mg | 5mg | 10mg |
---|
1 mM | 2.46 ml | 12.301 ml | 24.601 ml |
5 mM | 0.492 ml | 2.46 ml | 4.92 ml |
10 mM | 0.246 ml | 1.23 ml | 2.46 ml |
5 mM | 0.049 ml | 0.246 ml | 0.492 ml |
Last Update:2024-01-02 23:10:35
5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyriMidin-3-yl]quinoline - Introduction
5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline is a chemical that is also known as a reduced cholesterol absorption inhibitor. The following is a description of the properties, uses, formulation and safety information of 5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline:
1. Properties: 5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline is a white crystalline powder with a unique chemical structure. Its molecular formula is C24H23N3O2 and its molecular weight is 385.46g/mol. 5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline has good solubility and is soluble in organic solvents such as dimethyl sulfoxide.
2. Uses: 5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline is mainly used as a reagent in the field of pharmaceutical research, in particular, it is widely used in the development of cholesterol absorption inhibitors. As an inhibitor, it can inhibit the activity of cholesterol transporter (NPC1L1) in intestinal cells, thereby reducing the absorption of cholesterol and helping to reduce cholesterol levels in the blood.
3. Preparation Method: The preparation of 5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline is usually carried out by an organic synthesis method. The synthesis process involves a series of chemical reactions, such as condensation reactions and the formation of cyclic structures. Specific synthetic methods and process conditions will vary depending on research needs and process development.
4. Safety Information: Limited information is currently available regarding the safety and toxicity of 5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline. Since it is mainly used in the laboratory field, it is necessary to follow the relevant safe operation guidelines when using it. When necessary, wear personal protective equipment, follow reasonable laboratory procedures, and avoid contact with skin, eyes, and respiratory tract. In case of any accident, seek medical help immediately.
Please note that the information here is for reference only, specifically using 5-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a] When pyrimidin-3-yl]quinoline or any chemical substance, it should be fully studied and evaluated according to the specific situation, and follow the relevant safety operation guidelines.
Last Update:2024-04-09 21:04:16